Response and Resistance: A Tale of Tumor and T Cells
Scientific Workshop
Frederick Locke, MD
2:41 - 3:27 p.m.
Room 28 A-D

Scientific Workshop: Functional Laboratory Studies of Resistance
Moderator Introduction
Frederick Locke, MD
3:42 - 4:18 p.m.
Room 28 A-D

247: Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Oral 
Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP
2:00 p.m.
San Diego Ballroom AB

354: High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasm
Oral
Zhuoer Xie, MD, MS
5:15 p.m.
Ballroom 20 AB

2415: Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
Poster
Fatima Tuz Zahra, MBBS
5:30 - 7:30 p.m.
Halls G-H

1995: Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
Poster
Rachid Baz, MD
5:30 - 7:30 p.m.
Halls G-H

1906: De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Imminosuppression
Poster
Mark B. Meads, PhD
5:30 - 7:30 p.m.
Halls G-H

2004: Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Poster
Fnu Amisha, MD
5:30 - 7:30 p.m.
Halls G-H

2071: Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Poster
Hany Elmariah, MD, MS
5:30 - 7:30 p.m.
Halls G-H

1843: High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
Poster
Jeremy V. DiGennaro, DO
5:30 - 7:30 p.m.
Halls G-H

1848: Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction
Poster
Wael Gamal, PhD
5:30 - 7:30 p.m.
Halls G-H

2229: Mechanistic Learning Reveals the Reciprocal Cell Fate Transitions That Drive Disease Progression in B-Cell Acute Lymphoblastic Leukemia
Poster
Sadegh Marzban
5:30 - 7:30 p.m.
Halls G-H

2130: Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamid
Poster
Jena Schmitz, DNP, APRN, FNP-C
5:30 - 7:30 p.m.
Halls G-H

1533: Inflammatory Transcriptional Signature Can Discriminate De Novo and Secondary AML
Poster
Ken Phong Phong Dao
5:30 - 7:30 p.m.
Halls G-H

1845: Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
Poster
Rami S. Komrokji, MD
5:30 - 7:30 p.m.
Halls G-H

1520: A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Poster
Onyee Chan, MD
5:30 - 7:30 p.m.
Halls G-H

481: A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
Oral
Andrew T. Kuykendall, MD
9:30 a.m.
Grand Hall C

3785: Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Workshop Poster
Lauren C. Peres, PhD, MPH
6:00 - 8:00 p.m.
Halls G-H

3784: Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
Poster
Ariel F. Grajales-Cruz, MD
6:00 - 8:00 p.m.
Halls G-H

3021: Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
Poster
Shrinjaya B Thapa, MD
6:00 - 8:00 p.m.
Halls G-H

3065: A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma
Poster
Hayder Saeed, MD
6:00 - 8:00 p.m.
Halls G-H

3227: Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
Poster
Hammad Tashkandi, MD
6:00 - 8:00 p.m.
Halls G-H

3217: Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
Poster
Rami S. Komrokji, MD
6:00 - 8:00 p.m.
Halls G-H

3228: IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
Poster
Rami S. Komrokji, MD
6:00 - 8:00 p.m.
Halls G-H

2820: Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
Poster
Katherine Tobon, PharmD, BS
6:00 - 8:00 p.m.
Halls G-H

3060: Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma 
Poster
Sara Niyazi, DO
6:00 - 8:00 p.m.
Halls G-H

3091: CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) – a Multicenter Retrospective Study
Poster
Ning Dong, MD MS
6:00 - 8:00 p.m.
Halls G-H

2622: Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis
Poster
Moazzam Shahzad, MD
6:00 - 8:00 p.m.
Halls G-H

896: Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
Oral
Doris K. Hansen, MD
3:00 p.m.
Pacific Ballroom Salons 24-26

868: Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
Oral
Sameh Gaballa, MD
3:30 p.m. 
Pacific Ballroom Salons 15-17

936: Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel 
CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
Oral
Doris K. Hansen, MD
4:00 p.m.
San Diego Ballroom AB

1046: Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
Oral
David Sallman, MD
4:45 p.m.
Room 6A

1004: CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
Oral
Rami S. Komrokji, MD
4:45 p.m.
Grand Hall D

1031: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial 
Oral
Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP
5:30 p.m.
Pacific Ballroom Salons 24-26

989: A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Oral
Julio C. Chavez, MD
5:30 p.m.
Pacific Ballroom Salons 18-19

3947: Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades
Poster
Moazzam Shahzad, MD
6:00 - 8:00 p.m.
Halls G-H

4837: Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
Poster
Bijal D Shah, MD
6:00 - 8:00 p.m.
Halls G-H

5052: U.S. Expert Consensus on Dening Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
Poster
Onyee Chan, MD
6:00 - 8:00 p.m.
Halls G-H

4590: Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
Poster
Rami S. Komrokji, MD
6:00 - 8:00 p.m.
Halls G-H

4826: Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
Poster
Nelli Bejanyan, MD
6:00 - 8:00 p.m.
Halls G-H

5168: Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
Poster
Omar Castaneda, MD
6:00 - 8:00 p.m.
Halls G-H

4991: A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears
Poster
Palak Dave
6:00 - 8:00 p.m.
Halls G-H

4645: The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma
Poster
Praneeth Reddy Sudalagunta, PhD
6:00 - 8:00 p.m.
Halls G-H

4692: Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
Poster
Ziad Abuhelwa, MD, MPH
6:00 - 8:00 p.m.
Halls G-H

4740: Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
Poster
Filip Ionescu, MD, MS
6:00 - 8:00 p.m.
Halls G-H

4871: Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
Poster
Mariola A Vazquez-Martinez, MD
6:00 - 8:00 p.m.
Halls G-H

4332: Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
Poster
David Sallman, MD
6:00 - 8:00 p.m.
Halls G-H

4561: Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelobrosis and Analysis of Early Treatment Outcomes
Poster
George Concepcion, MD
6:00 - 8:00 p.m.
Halls G-H

5103: Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
Poster
Moazzam Shahzad, MD
6:00 - 8:00 p.m.
Halls G-H

4881: Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
Poster
Abida Babu, MBBS
6:00 - 8:00 p.m.
Halls G-H

4589: The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
Poster
Ziad Abuhelwa, MD, MPH
6:00 - 8:00 p.m.
Halls G-H

4979: Quantification of Transition Rates in B-Cell Acute Lymphoblastic Leukemia Identies Structural Relationships between Cell States
Poster
Jeffrey West, PhD
6:00 - 8:00 p.m.
Halls G-H

1048: Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
Poster
Hany Elmariah, MD, MS
6:00 - 8:00 p.m.
Halls G-H

4803: Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy
Poster
Wael Gamal, PhD
6:00 - 8:00 p.m.
Halls G-H

4936: Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation
Poster
Moazzam Shahzad, MD
6:00 - 8:00 p.m.
Halls G-H

4270: Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia 
Poster
Onyee Chan, MD
6:00 - 8:00 p.m.
Halls G-H

5190: Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
Poster
Faustine Ong, MD
6:00 - 8:00 p.m.
Halls G-H